Cancers, Vol. 13, Pages 214: Immune-Checkpoint Inhibitors in B-Cell Lymphoma

Cancers, Vol. 13, Pages 214: Immune-Checkpoint Inhibitors in B-Cell Lymphoma Cancers doi: 10.3390/cancers13020214 Authors: Armengol Santos Fernández-Serrano Profitós-Pelejà Ribeiro Roué For years, immunotherapy has been considered a viable and attractive treatment option for patients with cancer. Among the immunotherapy arsenal, the targeting of intratumoral immune cells by immune-checkpoint inhibitory agents has recently revolutionised the treatment of several subtypes of tumours. These approaches, aimed at restoring an effective antitumour immunity, rapidly reached the market thanks to the simultaneous identification of inhibitory signals that dampen an effective antitumor response in a large variety of neoplastic cells and the clinical development of monoclonal antibodies targeting checkpoint receptors. Leading therapies in solid tumours are mainly focused on the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1) pathways. These approaches have found a promising testing ground in both Hodgkin lymphoma and non-Hodgkin lymphoma, mainly because, in these diseases, the malignant cells interact with the immune system and commonly provide signals that regulate immune function. Although several trials have already demonstrated evidence of therapeutic activity with some checkpoint inhibitors in lymphoma, many of the immunologic lessons learned from solid tumours may not directly translate to lymphoid malignancies. In this...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research